Background: The reactive center loop (RCL) of native antithrombin is partially inserted in the main serpin body. It must be fully exposed for optimal inhibitory function. Objective: To test the hypothesis that P 14 -s2B interaction affects loop insertion in antithrombin. By mutating Phe 274 to Tyr 274 , the objective was to introduce P 14 -s2B interaction in antithrombin. Methods: Site-directed mutagenesis and affinity chromatography were used to obtain purified recombinant protein. Antithrombin's ability to form sodium dodecyl sulfate (SDS)-stable complex with thrombin, stoichiometry of thrombin inhibition, second-order rate constant for thrombin and factor Xa (fXa) inhibition (M À1 s À1 ), and heparin dissociation constant (K D ; tryptophan fluorescence emission spectra) were determined. Results and Conclusion: A marginal, but inconclusive, difference between the wild type and the mutant was observed. The result highlights the variable effect of P 14 -s2B interaction in different serpins. Alternate hypothesis for achieving loop expulsion is proposed.
Introduction
Antithrombin, a member of serine proteinase inhibitor family of proteins, inhibits thrombin and factor Xa (fXa). The rate of fXa inhibition increases several folds due to the binding of a specific pentasaccharide sequence of heparin to antithrombin. 1 As a result, the partially buried reactive center loop (RCL) is expelled from the main serpin body. 2 Thrombin's inhibition rate-enhancement process requires binding of a much longer heparin chain that includes the pentasaccharide portion. 3 The release of buried RCL from the main serpin body and its subsequent insertion after loop cleavage 4 are important steps in antithrombin's activation and enzyme inhibition, respectively.
Structural and biochemical evidence shows that residue P 14 (nomenclature as per Schechter and Berger 5 ) is vital for RCL's insertion into sheet A of serpin. 2, [6] [7] [8] Following loop insertion, the P 14 residue is positioned adjacent to sheet B's conserved residue, which leads to P 14 -s2B Hydrogen (H)-bond interaction in many serpins. 9 In PAI-2, disruption of this interaction interferes with RCL insertion. 10 Due to the presence of s2B tyrosine at position 274 (instead of the conserved phenylalanine), antithrombin is one of the few inhibitory serpins that lacks P 14 -s2B interaction. Unlike majority of the inhibitory serpins, antithrombin's RCL is partially buried in the main serpin body in protein's native state. It is thus hypothesized that the unusual presence of a partially inserted RCL in antithrombin is as a result of the unusual lack of P 14 -s2B interaction. Differently stated, the hypothesis is that the P 14 -s2B interaction affects RCL insertion into sheet A of antithrombin.
The biological and clinicopathological importance of the study lies in its contribution to the larger aim of constructing antithrombin that would not require heparin assistance for its activation. Experiments were designed to test the hypothesis. The underlying assumption is that the mutation would introduce the P 14 -s2B H-bond interaction.
Material and Methods

Expression of Mutant F274Y Antithrombin
Site-directed mutagenesis was used to insert the mutation at residue position 274 in antithrombin gene (pFastBac1). The primer sequences were as follows (bold nucleotides indicate the mutation): 5 0 ctt-gag-ttg-ccc-tac-aaa-ggt-gat-gac 3 0 3 0 gaa-ctc-aac-ggg-atg-ttt-cca-cta-ctg 5 0
The polymerase chain reaction (PCR) conditions were initial denaturation at 95 C/30 s, followed by 18 cycles of the following set: 95 C/30 s, 55 C/1 min, and 68 C/11 min. Transformation was performed using the Quick Change Site-Directed Mutagenesis Kit (Stratagene, La Jolla, California), with XL1-Blue supercompetent cells. DpnI-digested plasmid (4.0 mL) was added to 50 mL of supercompetent cells and incubated on ice for 30 minutes, followed by heat pulse (42 C/45 s). The cells were grown in Luria Bertani broth (LB; 37 C/1 h, 500 mL final volume), followed by blue-white colony screening on LB agar that contained 80 mg/mL X-gal, 20-mmol/L IPTG (Isopropyl thiogalactoside), and 50 mg/mL ampicillin (final pH 7.0). Plasmid from selected white colonies was isolated (Midiprep Kit, Invitrogen, Carlsbad, California) and sequenced to confirm the mutation. Transposition of antithrombin gene was done in DH10 Bac supercompetent cells using 1:20 plasmid-to-cell ratio. The mix was incubated on ice for 30 seconds, followed by a heat pulse of 42 C/45 s, incubation on ice (2 minutes), addition of SOC media (900 mL), and incubation (37 C/4 h at 160 rpm). Various cell dilutions were plated on Luria agar having IPTG (40 mg/mL), Bluo-gal (200 mg/mL), kanamycin (50 mg/mL), gentamycin (7 mg/mL), and tetracyclin (10 mg/ mL). Bacmid DNA from white colony culture was isolated and stored at À20 C until used. Insect cells (Sf9) were transfected as follows: log phase cells (1 Â 10 6 ) were aseptically added to 2.0 mL of Sf900 media containing penicillin (50 U/mL) and streptomycin (50 U/mL) and incubated (27 C/1 h). Cellfectin solution was added to various dilutions of bacmid DNA made in Sf (Spodoptera frugiperda) II SFM (Serum Free Media) (50-, 20-, 10-, 6.6-, and 5-fold, respectively; 100 mL final volume) to give a 16.6-fold dilution, followed by incubation at 27 C/5 h. The media was replaced with 2.0 mL of Sf900 media containing penicillin and streptomycin (1% each), followed by incubation at 27 C/72 h. When the cell number went down by approximately 60% (microscopic examination), the supernatant containing the virus was scaled up and used for infecting Sf9 cells (2 Â 10 6 cells). Both EDTA and phenylmethanesulphonylfluoride (PMSF) were added to the supernatant at 10 and 1 mmol/L, respectively, final concentrations, respectively. The final pH of the supernatant was adjusted to 7.4 and antithrombin's presence confirmed by Radial Immunodiffusion Assay (The Binding Site, San Diego, California). Laboratory stock of recombinant wild type antithrombin was used as the control.
Antithrombin Purification
Heparin-agarose affinity column was used to isolate the expressed protein from the media. 11 The column was equilibrated with *100 mL of phosphate buffer containing 0.5 mol/L NaCl (0.5 mol/L NaCl, 20 mmol/L sodium phosphate [dibasic], and 0.1 mmol/L EDTA adjusted to pH 7.4), followed by media loading over a 24-hour period at 4 C. The column was washed with phosphate buffer containing 0.5 mol/L NaCl for 1 hour (rate: 2.0 mL/1 minute) to elute out impurities bound to the column. The gradient for protein elution was set to range from 0.5 to 3.0 mol/L NaCl. Protein elution was monitored by the increase in fluorescence intensity (excitation: 280 nm).
Concentration of the protein from the pooled fractions was done using Amicon concentrator (10 kDa cutoff, 4.5-mm diameter filter; Millipore, Billerica, Massachusetts). Buffer exchange was done with 0.1 mol/L NaCl. Final protein concentration was determined spectrophotometrically (molar absorption coefficient: 37, 700 M À1 cm À1 ). 11, 12 
Confirmation of Antithrombin's Purity and Inhibitory Activity
A mix of equal volumes (2.0 mL) of mutant (9.07 mmol/L) and thrombin (10 mmol/L) was incubated at 37 C/30 min to allow complex formation, followed by sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE; 75 V/45 min/10%). Coomassie blue staining was used to detect the protein bands. Controls included mutant alone (4.0 mL, 9.07 mmol/L), wild type alone (4.0 mL, 23.6 mmol/L), thrombin alone (4.0 mL, 10.0 mmol/L), and wild type antithrombin (2.0 mL, 23.6 mmol/L) incubated with thrombin (2.0 mL, 10 mmol/L; 37 C/30 min).
Determination of Stoichiometry of Thrombin Inhibition
The basic methodology has been described earlier. 11 A constant concentration of thrombin (50 nmol/L) was incubated at 25 C/24 h with varying concentrations of mutant antithrombin (10, 20, 30, 40, and 50 nmol/L) in a 100-mL volume. From the incubated sample, 10.0 mL was added to 990 mL of 100 mmol/L thrombin substrate (S-2238; Chromogenix, USA) containing 50 mg/mL Polybrene (Sigma, St Louis, Missouri) in a cuvette. The initial rate of substrate hydrolysis due to residual enzyme activity was monitored from the linear absorbance increase (l: 405 nm). The inhibition stoichiometry was obtained by extrapolating linear least square fits of the decrease in enzyme activity, with increasing molar ratio of the inhibitor to enzyme to yield complete enzyme inhibition. Stoichiometry of inhibition (SI) is given as moles of inhibitor needed per mole of proteinase for its complete inhibition.
Kinetics of Antithrombin-Proteinase Association
The second-order rate constants for the association of antithrombin with fXa and thrombin were measured under pseudo-first-order conditions, that is, molar excess of inhibitor over enzyme, both in the absence and in the presence of pentasaccharide (H 5 ) and full-length heparin (H 50 ). 11 The reaction mixture consisted of 200 nmol/L of antithrombin and 0, 1, 2, or 3 nmol/L of H 5 or H 50 (final volume of mix being 90 mL). Thrombin or fXa (10 mL) was added to the incubated reaction mix to give a final enzyme concentration of 5 nmol/L (fXa) or 10 nmol/L (thrombin). The mix was further incubated for a specified time (ranging from 25 seconds to 70 minutes), after which 900 mL of 100 mmol/L chromogenic substrate containing Polybrene was added to each time point sample. The time-dependent decrease in enzyme activity measured from the initial rate of chromogenic substrate hydrolysis of quenched samples was computer-fitted by a single exponential function to obtain the observed pseudo-first-order rate constant, k obs , as per the following equation:
where k obs is first-order rate constant, [E] 0 is the initial enzyme concentration, and [E] t is the enzyme concentration at time t. Apparent second-order association rate constants for uncatalyzed and catalyzed reactions were obtained from the least square slope of the linear dependence of k obs on the antithrombin [AT] or the heparin concentration [H] in accordance with the equation that applies when [AT] 0 >> [H] 0 .
The equation for the uncatalyzed reaction is:
where k is the second-order rate constant. The equation for the heparin-catalyzed reaction is:
where k H is the second-order rate constant for the heparincatalyzed reaction, and the term multiplying it represents the antithrombin-heparin complex concentration, which under experimental conditions was approximated by [H] o . The k obs for the uncatalyzed reaction was subtracted from the k obs in the presence of heparin to get the absolute value for the first-order rate constant due to heparin-antithrombin complex alone. A linear regression fit of k obs values at 0, 1, 2, and 3 nmol/L heparin concentration was used to obtain the second-order rate constant value for the catalyzed reaction.
Determination of Heparin Dissociation Constant (K D ; Tryptophan Fluorescence Emission Spectra)
Dissociation constant for binding of heparin to antithrombin was determined by following the change in fluorescence during heparin titration. 11 Measurements were made on an SLM 8000 spectrofluorometer (excitation at 280 nm, monitoring at 345 nm with a 4-nm excitation, and 16-nm emission bandpass using Data were fitted to the equation: 
Results
Mutant antithrombin (F274Y) was successfully expressed in insect cells. The molecular weight was approximately 50 kDa (SDS-PAGE; Figure 1, lanes 1-3) . It was comparable to the wild type antithrombin (Figure 2, lane 1 vs 2) . Correct folding of the expressed protein was confirmed by checking its ability to form SDS-stable complex with target proteinase. The result showed that majority of the antithrombin protein could form complex and was therefore active (Figure 2, lanes 4 and 5) . The stoichiometry of thrombin inhibition of mutant was 1:1 (Figure 3) , indicating that the rate and extent of reactive center loop insertion into b sheet A was similar to the wild type.
The percentage of tryptophan fluorescence change in mutant antithrombin during heparin pentasaccharide titration was *35% and 28% for the mutant and wild type antithrombin, respectively (Figure 4 ). Both the values are within the acceptable range for wild type antithrombin. 13 The basal fluorescence of the mutant was lower than the wild type, indicating the absence of RCL expulsion in the native state of the mutant. The equilibrium dissociation constant values (K D ) for heparin binding to antithrombin are reported in Table 1 . The values for pentasaccharide binding to antithrombin (wild type and mutant) at I.30 showed less binding affinity as compared to values at I.15 (ie, lower ionic strength). This is in accordance with previously reported trends. 14 The difference in the heparin pentasaccharide-binding affinity of wild type and mutant F274Y ranged between 1.2-and 1.5-fold.
The second-order rate constant value for enzyme inhibition by wild type and mutant antithrombin are shown in Table 2 . In the absence of heparin pentasaccharide, the mutant has only marginally higher inhibition rate (ie, by 2.0-fold) compared to the wild type. The fold value increases slightly in the show similar molecular weight for both the antithrombins, that is, *50 kDa as seen in Figure 1 ). Lanes 4 and 5 show dense, highmolecular-weight bands of antithrombin (AT)-thrombin (Thr) complex. presence of heparin pentasaccharide (enhanced by 2.7-fold). It thus appears that the presence of a conserved residue at position 274 maybe somewhat conducive for H 5 's action on antithrombin. The mutant inhibits thrombin at a rate comparable to the wild type (difference of up to 1.4-fold). In the presence of H 50 , the mutant's thrombin inhibitory rate lags behind the wild type by up to 2.0-fold. This difference is marginal and may indicate that the nonconserved residue is conducive to full-length heparin's enzyme-inhibiting action.
Discussion
Tyrosine at amino acid position 274 is a conserved residue in majority of the inhibitory serpins. Therefore, its replacement with phenylalanine, as in antithrombin, is likely to have a structural/functional effect. The most obvious is the absence of P 14 -s2B pairing in antithrombin. This pairing is observed in majority of the inhibitory serpins. For example, in PAI-2, it plays an important role in RCL insertion into the main serpin body, and disruption of this pairing prevents the cleaved loop from inserting into b sheet A. 10 Antithrombin naturally lacks this interaction, and yet, its cleaved loop inserts into b sheet A. This indicates that unlike majority of the inhibitory serpins, the P 14 -s2B interaction is not necessary for the burial of cleaved RCL into sheet A. The fact, however, does not completely rule out a role for P 14 -s2B pairing in RCL insertion as antithrombin is one of the few serpins that have the RCL inserted into the main serpin body prior to loop cleavage, that is, in the native state. Could this unusual structural feature be the result of the unusual absence of P 14 -s2B pairing in antithrombin? To find out, experiments were carried out on the premise that the partial loop-inserted native state in antithrombin is due to the absence of P 14 -s2B interaction, and therefore, the presence of this interaction would allow antithrombin to fold into a fully loop-expelled state.
The stoichiometry data and the proteinase-enzyme complex formation data indicated no conclusive difference between the wild type and the mutant antithrombin (1:1 stoichiometry value and dense bands of antithrombin-thrombin complex on SDS-PAGE). The result is consistent with the kinetic experiment result, which showed a comparable second-order rate constant value in the absence of H 50 for thrombin inhibition by both anithrombin varieties (0.93-to 1.4-fold difference).
Complete RCL expulsion in mutant antithrombin is accompanied by a 35% enhancement in tryptophan fluorescence. 8 The acceptable range of this value is wide for wild type antithrombin. 14 Accordingly, both antithrombin species reported here underwent similar percentage fluorescence change (approximately 35% and 28%, respectively), thus ruling out loop expulsion in the mutant prior to heparin titration.
The equilibrium dissociation constant, KD, value for heparin pentasaccharide binding to the mutant was 1.2-to 1.5-fold higher than the wild type. It does not conclusively indicate a difference in the heparin-binding affinity. The KD values obtained from the curve-fit equation can vary significantly, with small errors in concentration and on F0, DFmax, and n values. The loop expulsion effect of the mutation, if present, is too small to change the KD of the mutant by a value large enough to be detected by heparin pentasaccharide titration.
The kinetic data showed a maximum 2-fold enhancement in the rate of fXa inhibition of the mutant in the absence of heparin pentasaccharide. This further increases to 3-fold in the presence of H 5 . It is known that partial expulsion of RCL is accompanied by enhanced H 5 affinity. 2 However, the observed fold increase is quite marginal to be conclusive for enhanced H 5 affinity.
In the absence of H 50 , the thrombin inhibition rate of the mutant remains similar to the wild type. This is consistent with the stoichiometry of thrombin inhibition data presented earlier. However, H 50 may preferentially bind to wild type antithrombin as there is a 2-fold enhancement in wild types thrombin inhibition rate in the presence of H 50 . That H 50 (and not H 5 ) preferentially (though marginally) enhances the rate of wild type may indicate that residues outside the pentasaccharidebinding pocket in the mutant maybe affected by the mutation, 13 thereby decreasing the effectiveness of H 50 to bridge antithrombin and thrombin.
Overall, the results showed marginal, but inconclusive, difference between the two antithrombin species. The study 10 emphasizes that even though the P 14 -s2B interaction is conserved in serpin family, the strength of its effect on the RCL varies from serpin to serpin, as evident from the marginal effect observed in antithrombin versus huge difference in plasminogen activator inhibitor-2. Future structural work on this aspect of antithrombin should use alternate methods such as X-ray crystallography, atomic force microscopy, and so on.
A new hypothesis for achieving loop expulsion in antithrombin is proposed as follows: residues forming the inserted portion of the RCL if mutated one-on-one to neutral and simple structured amino acid such as glycine could modify the bonding forces that keep the loop in the inserted. This is expected to result in a fully loop-expelled conformation of native antithrombin. A nonbulky residue in the inserted portion of the RCL, which is capable of forming side-chain H-bond interaction is expected to promote placement of the cleaved RCL between s3A and s5A by forming H-bond interaction with its neighbors, thus minimizing the chances that such a mutant may become a substrate. Alternately, the residues in sB in the vicinity of the inserted portion of the RCL may also be mutated to nonbulky, neutral residues to prevent bonding interaction with the RCL. Unlike RCL mutants, mutation in sB is not likely to hinder the insertion of cleaved RCL in sheet A, thus preventing the mutant from becoming a substrate.
